Laborie Medical Technologies Acquires Pelvalon

Innovative product added to Laborie's growing portfolio that treats underserved patient community

Laborie Medical Technologies Corp. (Laborie) a specialist medical technology company, announced today that it has acquired Pelvalon, Inc., a privately held medical device company located in Redwood City, CA.

Pelvalon has developed an innovative product called the Eclipse™ System, a non-surgical, patient-controlled device for women suffering from fecal incontinence (FI). FI is a pelvic floor disorder that affects one in ten women. The Eclipse has a compelling clinical profile validated in multiple studies, is FDA-cleared and has established reimbursement. The product is simple, safe and effective and its reputation has spurred demand from numerous healthcare professionals and patients across the country.

“Laborie’s mission every day is to operate as a world-class specialist medical company making and advancing technologies that preserve and restore human dignity,” said Michael Frazzette, President & CEO of Laborie. “Our mission is well served by the addition of Eclipse™ to help patients who suffer from this difficult condition.”

“I am grateful for the dedicated work of my colleagues to bring the therapy to this point, and we are delighted that Laborie will be able to scale and deliver Eclipse™ to the doctors and patients who need it,” said Miles Rosen, Pelvalon Founder and CEO. “Laborie’s mission aligns perfectly with this technology.”

“Patricia Industries is committed to supporting Laborie in its mission to provide patients and healthcare professionals with innovative and effective therapeutic and diagnostic technologies that preserve and restore human dignity,” said Yuriy Prilutskiy, Head of Patricia Industries North America, a part of Investor AB, and owner of Laborie. “This acquisition further supports Laborie’s long-term growth, leverages Patricia Industries’ healthcare and life sciences expertise and aligns with our organization’s purpose of creating value for people and society by building strong and sustainable businesses.”

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version